Asthma bronchiale und chronisch-obstruktive Lungenkrankheit (COPD): Unterschiede und gemeinsamkeiten

Internist

Volumn 40, Issue 8, 1999, Pages 837-843

  Ullmer, E ^a   Soler M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; FLUTICASONE; IMMUNOSTIMULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; STEROID; THEOPHYLLINE;

ANAMNESIS; ASTHMA; BRONCHUS HYPERREACTIVITY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; HUMAN; INHALATION; LUNG DIFFUSION CAPACITY; LUNG EMPHYSEMA; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; SHORT SURVEY;

ASTHMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PROGNOSIS; RISK FACTORS;

EID: 0032839073     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050408     Document Type: Article

References (26)

1. ATS Statement (1995) Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152:S77-120
2. Kroegel C (1998) Pathogenetische Grundlagen des Asthma bronchiale. In: Asthma bronchiale. Thieme Verlag: 13-51
3. Jeffery PK (1998) Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 53:129-136
4. Belman MJ, Betnick WC, Shin JW (1996) Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153:967-975
5. Wyser C, Solèr M, Perruchoud AP (1997) Neue Aspekte in der Behandlung des Asthma bronchiale und chronisch obstruktiver Lungenkrankheiten. Schweiz Med Wochenschr 127:885-890
6. The British Guidelines on Asthma Management (1997). Thorax 52 [Suppl1]:1-21
7. Wettengel R, Berdel D, Cegla U, Fabel H, Geisler L, Hofmann D, Krause J, Kroidl RF, Lanser K, Leupold W, Lindemann H, Matthys H, Meister R, Morr H, Nolte D, Schultze-Werninghaus G, Sill V, Sybrecht GW, Thal W, Worth H (1994) Empfehlungen der Deutschen Atemwegsliga zum Asthmamanagement bei Erwachsenen und bei Kindern. Med Klinik 89:57-67
8. 2-agonists in asthma therapy. CHEST 113:1095-1108
9. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne, Bernes PJ, Ullman A (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337:1405-1411
10. Woolcock A, Lundback BO, Ringdal N, Jacques LA (1996) Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153:1481-1488
11. Greening AP, Ind PW, Morthfiled M, Shaw G (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344:219-224
12. Horowitz RJ, McGill KA, Busse WW (1998) The role of leukotriene modifiers in the treatment of asthma. Am J Respir Cirt Care Med 157:1363-1371
13. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N et al. (1997) Comparison of addition of theophylline to inhaled steroid with doubling the dose of inhaled steroid in asthma. Eur Respir J 10:2754-2760
14. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J et al. (1995) Optimal assessment and management of chronic obstructive pulmonary disease (COPD). ERS-consensus statement. Eur Respir J 8:1398-1420
15. Wettengel R, Böhning W, Cegla U, Criée C, Fichter J et al. (1995) Empfehlungen der Deutschen Atemwegsliga zur Behandlung von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem. Med Klinik 90:3-7
16. Anderson W, Wisniewski M, Barbee R, Rickard KA (1997) Comparison of Serevent and ipratropium on pulmonary function in COPD patients reversible to ipratropium. Am J Respr Crit Care Med 155:A277
17. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C (1997) An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 10:815-821
18. Jones PW, Bosh TK in association with an international study group (1997) Quality of life changes in COPD patients treated with Salmeterol. Am J Respir Crit Care Med 155:1283-1289
19. Chanez P, Vignola AM, O'Shaugnessy R, Enander I, Li D, Jeffery PK, Bousquet J (1997) Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 155:1529-1534
20. Bourbeau J, Rouleau MY, Boucher S (1998) Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 53:477-482
21. Renkama TEJ, Schouten JP, Koe7die;ter GH, Postma DS (1996) Effects of long-term treatment with corticosteroids in COPD. CHEST 109:1156-1162
22. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J (1998) Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 351:773-780
23. Van Grunsven PM, van Schayck CP, Derenne JP, Kertjens HAM, Renkema TEJ, Postma DS et al. (1999) Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-anaylsis. Thorax 54:7-14
24. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ (1996) Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 154:407-412
25. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WD et al. (1994) Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1. The Lung Health Study. J Am Med Assoc 272:1497-1505
26. Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years' observation on male British doctors. Br Med J 309:901-910